5[2]Ouabdesselarn S, Hooper DC, Tankovic J, et al. Detection of gyrA and gyrB mutations in quinolone-resistant clinical isolates of Escherichia coli by single-strand conformational polymorphism analysis and determination of levels of resistance conferred by two different single gyrA mutations[J]. Antimicrob Agents Chernother, 1995, 39: 1667-1670.
6[3]Bagel S, Hiillen V, Wiedemann B, et al. Impact of gyrA and parC mutations on quinolone resistance, doubling time, and supercoiling degree of Escherichia coli [ J ]. Antimicrob Agents Chemother, 1999, 43:868 - 875.
7[4]Lehn N, Stower-Hoffmann J, Kott T, et al. Characterization of clinical isolates of Escherichia coli showing high levels of fluoroquinolone resistance[J]. J Clin Microbiol, 1996, 34(3): 597 -602.
8[5]Heisig P. Genetic evidence for a role of parC mutation in development of high-level fluoroquinolone resistance in Escherichia coli[J]. Antimicrob Agents Chemother, 1996, 40:879 - 885.
9[7]Deguchi T, Yasuda M, Nakano M, et al. Detection of mutations in the gyrA and parC genes in quinolone-resistant clinical isolates of Enterobacter clocae [J]. J Antimicrob Chemother, 1997, 40:543 - 549.
